Abiraterone (Zytiga)
Oral CYP17 inhibitor for metastatic castration-resistant and high-risk castration-sensitive prostate cancer.
What is Abiraterone?
What it targets
CYP17 (17α-hydroxylase / C17,20-lyase) — key enzyme in androgen synthesis
Who it may help
Men with metastatic castration-resistant or high-risk metastatic castration-sensitive prostate cancer
Why testing matters
PSA, testosterone, CT/MRI/bone scan, liver function, potassium, blood pressure required before starting
Which prostate cancer settings is Abiraterone used in?
| Metastatic castration-resistant prostate cancer (mCRPC) | Used when prostate cancer has spread and continues to grow despite castrate testosterone levels — after surgical or medical castration. Approved with prednisone. |
| Metastatic high-risk castration-sensitive prostate cancer (mCSPC) | Used in selected patients whose metastatic prostate cancer still responds to hormone-lowering therapy but carries high-risk features such as high Gleason score, visceral metastases, or multiple bone lesions. |
| Advanced prostate cancer — post-chemotherapy setting | Originally approved for use after docetaxel chemotherapy in mCRPC; now also used in the pre-chemotherapy mCRPC setting and in combination strategies. |
Who may benefit from Abiraterone?
Eligibility depends on prostate cancer stage, hormone sensitivity, prior treatment, organ function, and overall fitness. Your oncologist will assess all of these factors.
- Confirmed metastatic prostate cancer on imaging (CT, MRI, bone scan, or PSMA PET)
- Castration-resistant disease with testosterone at castrate levels despite ADT
- Metastatic high-risk castration-sensitive disease with ongoing ADT
- Adequate liver function — liver enzyme elevations may require dose modification
- Blood pressure controllable — hypertension is a known and manageable side effect
- Potassium level within normal range at baseline — monitored throughout treatment
- Able to take oral medication regularly and consistently once daily
- No severe, uncontrolled heart failure, recent myocardial infarction, or unstable arrhythmia
- Oncologist assessment that expected benefit outweighs individual risks
How does Abiraterone work?
- Step 1 — Blocking androgen production
- Step 2 — Starving the tumour of androgen signals
- Step 3 — Mineralocorticoid management with steroid
- Step 4 — Sustained androgen axis control
Tests needed before starting Abiraterone
| PSA test | Baseline PSA establishes the starting level for monitoring treatment response over time. |
| Testosterone level | Confirms castrate testosterone levels in mCRPC; guides ADT status review in mCSPC. |
| CT scan and bone scan / PSMA PET | Imaging to confirm metastatic disease, site of spread, and baseline disease burden. |
| Liver function tests (LFTs) | Required before and during treatment — hepatotoxicity monitoring is mandatory. |
| Renal function and electrolytes | Potassium level is especially important; hypokalaemia requires correction before starting. |
| Blood pressure measurement | Hypertension is a known effect — blood pressure must be assessed and managed. |
| Cardiac history review | Review for heart failure, arrhythmia, fluid retention, or uncontrolled hypertension. |
| Full medication review | CYP3A4 and CYP2D6 interactions; steroid history; anticoagulant use; herbal products. |
How is Abiraterone given?
Abiraterone is taken as oral tablets at home, once daily, alongside a low-dose steroid prescribed by your oncologist.
| Standard dose — mCRPC and mCSPC | 1000 mg abiraterone acetate once daily (standard tablets — Zytiga). |
| Micronised formulation | 500 mg once daily if the micronised formulation (Yonsa) is prescribed — not interchangeable. |
| Steroid co-medication | Prednisone 5 mg twice daily or prednisolone as directed — must be taken alongside Abiraterone. |
| Food restriction (standard tablets) | Take on an empty stomach — no food for at least 2 hours before and 1 hour after. Food raises exposure unpredictably. |
| Timing | Take at approximately the same time each day. Combine with ADT injections as scheduled by your oncologist. |
| Missed dose | Take the missed dose on the same day if remembered. If the next day has already started, skip and resume normally — never double dose. |
| Swallowing | Swallow tablets whole with water. Do not crush, break, or chew. |
| Duration | Treatment continues until disease progression, unacceptable toxicity, or oncologist decision. Not a fixed-course treatment. |
Clinical evidence and benefits of Abiraterone
Abiraterone has been studied in multiple large phase III trials in both mCRPC and mCSPC settings, with consistent improvements in survival outcomes and disease control.
| mCRPC — COU-AA-301 (post-docetaxel) | Significantly improved overall survival versus placebo plus prednisone in men with mCRPC previously treated with docetaxel. |
| mCRPC — COU-AA-302 (pre-chemotherapy) | Substantially prolonged radiographic progression-free survival and overall survival in men with asymptomatic or mildly symptomatic mCRPC who had not yet received chemotherapy. |
| mCSPC — LATITUDE trial | In men with high-risk metastatic castration-sensitive prostate cancer, Abiraterone plus ADT significantly improved overall survival and radiographic progression-free survival compared with ADT alone. |
| PSA response | Meaningful PSA declines are observed in a significant proportion of patients, providing an early indicator of treatment activity. |
| Symptom and quality-of-life outcomes | Delays in pain progression, skeletal events, and functional decline have been reported across mCRPC trials compared with placebo. |
| Survival benefit in earlier settings | Use in high-risk mCSPC with ADT extends the duration of hormone sensitivity and delays the onset of castration resistance. |
Individual outcomes vary depending on disease stage, prior treatment, tumour biology, and overall health. These represent published clinical trial data from selected patient populations.
Side effects of Abiraterone
Abiraterone is generally better tolerated than chemotherapy. Most side effects relate to its hormonal mechanism and the co-administration of prednisone. Regular monitoring allows early detection and management.
| Fatigue and weakness | Very common; related to androgen suppression and steroid use. Usually manageable with activity pacing. |
| High blood pressure | Common; mineralocorticoid excess effect. Monitor at home and report if readings are consistently high. |
| Low potassium (hypokalaemia) | Common; can cause muscle cramps, weakness, or cardiac symptoms. Regular electrolyte checks required. |
| Fluid retention and ankle swelling | Common; due to mineralocorticoid excess. Dietary sodium reduction and monitoring of weight help. |
| Liver enzyme elevations | Occurs in a subset of patients; usually detected on routine LFTs. Monitoring every 2 weeks initially. |
| Joint and muscle pain | Common; related to androgen suppression. Physiotherapy and appropriate analgesia can help. |
| Hot flashes | Very common; related to androgen deprivation. Typically mild and not requiring treatment changes. |
| Nausea and indigestion | Occasional; taking tablets on a completely empty stomach reduces nausea in most patients. |
| Urinary symptoms | Urinary frequency or urgency may occur; report significant changes to your oncologist. |
| Blood sugar changes | Prednisone use increases blood glucose — important to monitor in patients with diabetes or pre-diabetes. |
| Increased infection risk | Long-term steroid use modestly raises infection susceptibility. Report fever or signs of infection promptly. |
| Fracture and bone density risk | Androgen suppression reduces bone density over time. Bone-protective medicines may be recommended. |
Contact your doctor immediately if you develop:
- Chest pain, severe shortness of breath, or rapid or irregular heartbeat
- Severe muscle weakness, cramps, or confusion — possible sign of very low potassium
- Yellowing of the eyes or skin, dark urine, or severe nausea — possible liver toxicity
- Sudden severe swelling of legs, feet, or face with difficulty breathing
- Fainting, extreme dizziness, or sudden severe fatigue — possible adrenal crisis
- Signs of adrenal insufficiency after stopping prednisone — severe weakness, vomiting, low blood pressure
Safety precautions and drug interactions
Tell your oncologist and pharmacist about all medicines, supplements, and herbal products before starting Abiraterone.
- CYP3A4 strong inducers (e.g. rifampicin, phenytoin, carbamazepine, St John's Wort) substantially reduce Abiraterone levels — avoid if possible.
- CYP2D6 substrates with narrow therapeutic index (e.g. thioridazine, dextromethorphan) — Abiraterone inhibits CYP2D6; dose adjustment may be needed.
- Warfarin interaction — increased anticoagulation risk. INR monitoring required; anticoagulant substitution may be safer.
- Liver disease — pre-existing hepatic impairment increases hepatotoxicity risk. Severe hepatic impairment is a contraindication to standard dosing.
- Heart failure, recent MI, or uncontrolled arrhythmia — Abiraterone can exacerbate fluid retention and cardiac stress.
- Uncontrolled hypertension — must be treated before or alongside Abiraterone initiation.
- Diabetes — prednisone raises blood glucose; more frequent glucose monitoring required.
- Never stop prednisone or prednisolone suddenly — taper only under medical supervision.
- Pregnancy exclusion — Abiraterone is not for use in women. Male patients with female partners of childbearing potential should use effective contraception.
- Adrenal or pituitary conditions — adrenal stress response may be impaired; inform your oncologist before any surgery, illness, or invasive procedure.
Abiraterone combination treatments
Abiraterone is almost always used as part of a broader prostate cancer treatment strategy. Combinations vary by disease stage, prior therapy, and biomarker profile.
| Abiraterone + ADT (mCRPC and mCSPC) | Standard backbone: Abiraterone plus ongoing androgen deprivation therapy with prednisone or prednisolone in all approved settings. |
| Abiraterone + docetaxel (mCSPC) | Triplet therapy adding docetaxel to ADT plus Abiraterone is investigated in high-volume mCSPC; PEACE-1 and ARASENS data inform patient selection discussions. |
| Abiraterone + PARP inhibitors | In mCRPC with BRCA1/2 or other homologous recombination repair mutations, combinations with olaparib (PROpel) or niraparib (MAGNITUDE) are approved in selected countries. |
| Abiraterone + bone-protective agents | Denosumab or zoledronic acid may be added for bone metastases to reduce skeletal-related events, guided by bone scan findings and oncologist assessment. |
| Sequential use after other ARPI | Cross-resistance between Abiraterone and enzalutamide or other ARPIs is significant. Sequencing decisions depend on prior exposure, PSA trend, and genomic testing results. |
| Radiation therapy in combination | Radiation to symptomatic bone metastases or primary site may be used alongside systemic Abiraterone in selected patients. |
If Abiraterone stops working
Resistance to Abiraterone is common over time. Understanding the mechanism guides the choice of next treatment.
| Androgen receptor gene amplification | The androgen receptor gene is amplified or overexpressed, allowing cancer cells to respond to very low androgen levels that persist despite Abiraterone. |
| AR splice variants (AR-V7) | AR-V7 splice variant produces a truncated androgen receptor that lacks the ligand-binding domain — it is constitutively active and insensitive to both Abiraterone and enzalutamide. |
| CYP17 mutations and bypass pathways | Acquired CYP17 mutations or activation of bypass steroidogenesis pathways allow androgen production to resume despite treatment. |
| Next-line options after Abiraterone failure | Docetaxel or cabazitaxel chemotherapy, enzalutamide, darolutamide, PARP inhibitors (BRCA1/2-mutated), or PSMA-targeted radioligand therapy (177Lu-PSMA) depending on prior exposure and biomarker status. |
| BRCA1/2 and HRR mutations | Tumour genomic testing or liquid biopsy at progression helps identify BRCA1/2 or homologous recombination repair mutations — these patients may be eligible for PARP inhibitor therapy. |
| PSMA PET and radioligand therapy | In PSMA-positive mCRPC after Abiraterone and at least one line of taxane-based chemotherapy, 177Lu-PSMA-617 (Pluvicto) is an FDA-approved next-line option. |
Cost of Abiraterone by country
Generic abiraterone acetate has substantially reduced treatment costs in many countries. Cost varies by brand, formulation, treatment duration, and local insurance coverage.
| India | Generic abiraterone is available from multiple Indian manufacturers at significantly lower cost than branded Zytiga. Monthly cost of generics varies by manufacturer and retailer. Janssen patient access programmes may assist with brand access where relevant. |
| China | Zytiga received NMPA approval for mCRPC in 2015. It is listed on China's National Reimbursement Drug List (NRDL), substantially reducing out-of-pocket costs for eligible insured patients. Generic versions may also be available. |
| USA | Generic abiraterone acetate is available and is substantially less expensive than branded Zytiga. Patient assistance programmes (Janssen CarePath) are available for eligible patients. Insurance co-pay assistance may apply. |
| UK / Europe | Abiraterone is available through NHS England and national health systems in most EU countries for approved mCRPC and mCSPC indications. Co-pay and self-pay costs vary by country. |
| UAE / Gulf | Zytiga and/or generics are available through oncology centres. Private insurance coverage varies; self-pay costs are higher than in India or China. CancerFax can assist with access planning. |
Availability of Abiraterone globally
Abiraterone is available in most major oncology markets. Generic versions are widely accessible in India, China, and other middle-income countries.
India
Multiple Indian manufacturers produce approved generic abiraterone acetate 250 mg tablets. Available at oncology pharmacies and hospital dispensaries. One of the most cost-accessible markets globally for this drug.
China
Zytiga approved by NMPA in 2015 for mCRPC. Listed on China's NRDL, enabling reimbursement. Available at designated oncology hospitals in major cities. Generic versions may also be accessible.
USA
FDA-approved (Zytiga and generic versions). Widely available at oncology pharmacies. Generic abiraterone acetate became available after patent expiry, significantly reducing cost for patients and payers.
UK / Europe
EMA-approved for mCRPC and mCSPC. Available through NHS England for approved indications. European national health systems provide coverage in most countries, with local variations in criteria.
UAE / Gulf
Available at major oncology centres across the UAE, Saudi Arabia, and Gulf states. Both branded Zytiga and select generics may be accessible. Private insurance typically required for full coverage.
Abiraterone in ongoing and recent clinical trials
Research continues to refine how Abiraterone is best used — including in earlier disease settings, new combinations, and biomarker-selected populations.
| Triplet therapy in mCSPC | Trials evaluating docetaxel plus Abiraterone plus ADT (e.g. PEACE-1 in Europe) versus doublet combinations to identify patients most likely to benefit from intensified upfront therapy. |
| PARP inhibitor combinations | PROpel, MAGNITUDE, and TALAPRO-3 trials established combinations of Abiraterone with olaparib or niraparib in HRR-mutated and unselected mCRPC; ongoing biomarker refinement studies continue. |
| Earlier-stage disease | Trials exploring Abiraterone in high-risk localised or locally advanced prostate cancer in combination with radiation therapy or surgery — evaluating whether earlier systemic intervention improves long-term outcomes. |
| Sequencing and cross-resistance studies | Studies evaluating optimal sequencing of Abiraterone, enzalutamide, darolutamide, apalutamide, and chemotherapy, and the role of AR-V7 testing in guiding treatment selection. |
| Biomarker-stratified mCRPC trials | Ongoing studies identifying which patients benefit most from Abiraterone versus chemotherapy first, based on genomic profiling, AR copy number, and liquid biopsy findings. |
Your treatment journey with Abiraterone
Prostate cancer diagnosis and staging
Hormone sensitivity assessment
Baseline tests and oncology consultation
Starting Abiraterone
First 4–12 weeks — early monitoring
3-month response assessment
Long-term monitoring
If disease progresses
Questions to ask your oncologist about Abiraterone
- Do I have castration-sensitive or castration-resistant disease — and how does that affect my treatment plan?
- Why do I need to take prednisone alongside Abiraterone — and what happens if I stop?
- How should I take the tablets — are there food restrictions?
- How will we know whether Abiraterone is working?
- How often do I need liver function tests and blood pressure checks?
- Is a generic version of Abiraterone appropriate for me?
- What options are available if Abiraterone stops working?
- Can CancerFax help me access Abiraterone in India, China, or another country?
How CancerFax supports Abiraterone patients
CancerFax helps patients and families navigate Abiraterone access, specialist connections, and treatment planning for advanced prostate cancer across India, China, and internationally.
| Medical report review | Upload your PSA history, imaging reports, pathology, and blood results — our oncology team will review eligibility and explain what your results mean for Abiraterone suitability. |
| Prostate cancer specialist connection | We connect patients with oncologists and urological oncologists experienced in mCRPC and mCSPC management in India, China, UAE, Turkey, Thailand, and other countries. |
| Generic access support | We help patients identify quality-assured generic abiraterone manufacturers and access channels in India and other markets where cost is a barrier to treatment. |
| Second opinion coordination | If Abiraterone is not working, or you are uncertain about next steps, CancerFax arranges specialist second opinions — including review of genomic testing and next-line options. |
| Cross-border treatment planning | For patients in countries with limited access to Abiraterone or advanced prostate cancer care, CancerFax manages full coordination including hospitals, logistics, and follow-up. |
| Clinical trial matching | We help patients with progressing mCRPC identify relevant clinical trials for new combinations, PARP inhibitors, radioligand therapy, and other advanced options. |
Frequently asked questions about Abiraterone
Common questions from prostate cancer patients and families
Abiraterone acetate (Zytiga) is an oral androgen biosynthesis inhibitor that blocks the CYP17 enzyme, reducing androgen production in the testes, adrenal glands, and tumor tissue. Unlike standard androgen deprivation therapy (ADT) alone, which mainly suppresses testicular testosterone, Abiraterone also targets extra-testicular androgen sources that continue fuelling prostate cancer growth. It is taken daily with prednisone or prednisolone and is used alongside ongoing ADT in most settings.
Abiraterone blocks CYP17, which also reduces cortisol and aldosterone production. The body compensates by increasing ACTH, which stimulates mineralocorticoid production upstream of the block — causing high blood pressure, low potassium, and fluid retention. Prednisone or prednisolone (typically 5 mg twice daily) suppresses this compensation and reduces these side effects. Never stop the steroid suddenly without medical advice, as this can cause adrenal insufficiency.
PSA responses can often be seen within the first few weeks of treatment. Imaging-based response assessment is typically performed at 12 weeks or earlier if symptoms change. The full clinical benefit — including disease stabilisation and symptom improvement — is evaluated over several months. Your oncologist will monitor PSA trends, imaging results, and symptoms to assess how well treatment is working for you.
Yes — generic abiraterone acetate contains the same active ingredient at the same dose as branded Zytiga. Multiple real-world studies and regulatory assessments confirm bioequivalence. Generic versions are endorsed by NCCN and other major oncology guidelines. They are widely available in India and many other countries at substantially lower cost. Your oncologist can advise on suitable locally approved generic products.
A rising PSA on Abiraterone should be discussed with your oncologist promptly. A confirmed PSA rise on two successive tests, new symptoms, or radiographic progression may indicate treatment failure. Your doctor will review testosterone levels, imaging findings, and prior treatment history. Next options may include chemotherapy (docetaxel), another androgen receptor pathway inhibitor, PARP inhibitors for selected DNA repair mutations, PSMA-targeted radioligand therapy, or clinical trials.
Abiraterone acetate (standard tablets) must be taken on an empty stomach — no food for at least two hours before and one hour after the dose, as food substantially increases drug absorption and can raise exposure to unpredictable levels. There is a newer formulation (Yonsa/abiraterone acetate micronised) designed to be taken with food; however, the two formulations are not interchangeable. Always follow the specific instructions provided by your oncologist for the exact product prescribed to you.
Abiraterone can cause liver enzyme elevations and, rarely, serious hepatotoxicity. Patients with pre-existing liver disease require careful evaluation before starting treatment. Liver function tests are monitored at baseline, every two weeks for the first three months, and monthly thereafter. If significant liver enzyme rises occur, the dose may need to be interrupted or reduced. Patients with severe hepatic impairment are generally not candidates for standard Abiraterone dosing.